Format

Send to

Choose Destination
PLoS One. 2015 Jun 3;10(6):e0125837. doi: 10.1371/journal.pone.0125837. eCollection 2015.

Trends in Transmission of Drug Resistance and Prevalence of Non-B Subtypes in Patients with Acute or Recent HIV-1 Infection in Barcelona in the Last 16 Years (1997-2012).

Author information

1
Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi-Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
2
Huésped Foundation, Buenos Aires, Argentina.
3
Agency for Health Quality and Assessment of Catalonia (AQuAS), Barcelona, Spain.
4
Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi-Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain; Department of Microbiology. Barcelona Centre for International Health Research (CRESIB) Hospital Clínic, Barcelona, Spain.
5
Institute for Biomedical Research in Retroviruses and AIDS, Buenos Aires, Argentina.

Abstract

OBJECTIVES:

To evaluate the prevalence of transmitted drug resistance (TDR) and non-B subtypes in patients with acute/recent HIV-1 infection in Barcelona during the period 1997-2012.

METHODS:

Patients from the "Hospital Clínic Primary HIV-1 Infection Cohort" with a genotyping test performed within 180 days of infection were included. The 2009 WHO List of Mutations for Surveillance of Transmitted HIV-1 Drug Resistance was used for estimating the prevalence of TDR and phylogenetic analysis for subtype determination.

RESULTS:

189 patients with acute/recent HIV-1 infection were analyzed in 4 time periods (1997-2000, n=28; 2001-4, n=42; 2005-8, n=55 and 2009-12, n=64). The proportion of patients with acute/recent HIV-1 infection with respect to the total of newly HIV-diagnosed patients in our center increased over the time and was 2.18%, 3.82%, 4.15% and 4.55% for the 4 periods, respectively (p=0.005). The global prevalence of TDR was 9%, or 17.9%, 9.5%, 3.6% and 9.4% by study period (p=0.2). The increase in the last period was driven by protease-inhibitor and nucleoside-reverse-transcriptase-inhibitor resistance mutations while non-nucleoside-reverse-transcriptase inhibitor TDR and TDR of more than one family decreased. The overall prevalence of non-B subtypes was 11.1%, or 0%, 4.8%, 9.1% and 20.3 by study period (p=0.01). B/F recombinants, B/G recombinants and subtype F emerged in the last period. We also noticed an increase in the number of immigrant patients (p=0.052). The proportion of men-who-have-sex-with-men (MSM) among patients with acute/recent HIV-1 infection increased over the time (p=0.04).

CONCLUSIONS:

The overall prevalence of TDR in patients with acute/recent HIV-1 infection in Barcelona was 9%, and it has stayed relatively stable in recent years. Non-B subtypes and immigrants proportions progressively increased.

PMID:
26039689
PMCID:
PMC4454638
DOI:
10.1371/journal.pone.0125837
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center